Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy

BACKGROUND: Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However, Gemcitabine/Oxaliplatin (GEMOX) combination and Gemcitabine/Carboplatin (Gem/Carb) combinatio...

詳細記述

保存先:
書誌詳細
出版年:BMC Gastroenterol
主要な著者: Fiteni, Frédéric, Jary, Marine, Monnien, Franck, Nguyen, Thierry, Beohou, Eric, Demarchi, Martin, Dobi, Erion, Fein, Francine, Cleau, Denis, Fratté, Serge, Nerich, Virginie, Bonnetain, Franck, Pivot, Xavier, Borg, Christophe, Kim, Stefano
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2014
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4236575/
https://ncbi.nlm.nih.gov/pubmed/25117717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-230X-14-143
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料